TAPP Signs onto Letter to President Trump & Administrator Oz on Patient First Reforms

The Trade Alliance to Promote Prosperity recently signed onto a letter to President Trump and Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D. opposing potential price control measures included in the administration’s “Most Favored Nation” plan.

As TAPP has explained extensively, a Most Favored Nations scheme for prescription drug pricing could slow medical innovation and result in fewer cures being developed.  

In part, the coalition letter said, “A better approach would be to demand in ongoing trade negotiations that other rich countries commit to increasing spending on brand drugs, which will result in more new cures being developed and lower U.S. prices. Our research shows this can be done while lowering the total drug spending of these countries if they also allow more use of generics to offset higher brand drug prices… Accordingly, we ask that you reconsider any adoption of price controls and focus on regulatory changes that will increase price transparency and choice for patients.”

Read the full letter here.